{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:29Z","timestamp":1794047489628,"version":"4.8.0"},"reference-count":24,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"3","license":[{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Patients with relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) have a poor prognosis. Loncastuximab tesirine (Lonca), an antibody conjugate targeting CD19, has demonstrated significant clinical benefit in R\/R DLBCL in a global phase II LOTIS-2 study. In the China bridging pivotal phase II OL-ADCT-402-001 study, eligible patients aged \u226518 years with R\/R DLBCL who had failed \u22652 lines of systemic therapies were enrolled and treated every 3 weeks with 150 \u03bcg\/kg Lonca for two cycles; then 75 \u03bcg\/kg for subsequent cycles (up to 1 year). The primary endpoint was overall response rate (ORR) assessed by an independent review committee. Primary analyses for efficacy and safety were performed on the patients who received at least one treatment and had at least 6 months of follow-up following an initial documented response. As of data cutoff, 64 patients received Lonca (median 4.0 cycles; range, 1-17). The median number of prior lines of therapies was 3.0 (range, 2-12). The ORR was 51.6% (95% confidence interval [CI]: 38.7-64.2), and the complete response rate was 23.4%. Hematological events accounted for the majority of the most common (\u226515%) grade \u22653 treatment-emergent adverse events (TEAE), in which increased \u03b3-glutamyltransferase (25.0%), and hypokalaemia (18.8%) also were reported. Serious TEAE were reported in 35 of 64 patients with four fatal TEAE. In conclusion, Lonca monotherapy demonstrated clinically meaningful efficacy and was well-tolerated in heavily pretreated Chinese patients with R\/R DLBCL, which was consistent with the results of the LOTIS-2 study in Caucasian patients.<\/jats:p>","DOI":"10.3324\/haematol.2024.284973","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T15:41:53Z","timestamp":1725550913000},"page":"683-692","source":"Crossref","is-referenced-by-count":6,"title":["Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial"],"prefix":"10.3324","volume":"110","author":[{"given":"Ningjing","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keshu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenguang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"key":"73251","unstructured":"Li XQ, Li GD, Gao ZF, Zhou XG, Zhu XZ. Distribution pattern of lymphoma subtypes in China: A nationwide multicenter study of 10002 cases. J Diagn Concepts Pract. 2012; 11(02):111-115."},{"key":"73252","doi-asserted-by":"crossref","unstructured":"Liu W, Liu J, Song Y. Burden of lymphoma in China, 1990-2019: an analysis of the global burden of diseases, injuries, and risk factors study 2019. Aging (Albany NY). 2022; 14(7):3175-3190.","DOI":"10.18632\/aging.204006"},{"key":"73253","doi-asserted-by":"crossref","unstructured":"Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med. 2021; 384(9):842-858.","DOI":"10.1056\/NEJMra2027612"},{"key":"73254","doi-asserted-by":"crossref","unstructured":"Nastoupil LJ, Bartlett NL. Navigating the evolving treatment landscape of diffuse large B-cell lymphoma. J Clin Oncol. 2023; 41(4):903-913.","DOI":"10.1200\/JCO.22.01848"},{"key":"73255","doi-asserted-by":"crossref","unstructured":"Crump M, Neelapu SS, Farooq U. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017; 130(16):1800-1808.","DOI":"10.1182\/blood-2017-03-769620"},{"key":"73256","doi-asserted-by":"crossref","unstructured":"Sehn LH, Hertzberg M, Opat S. Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory DLBCL: survival update and new extension cohort data. Blood Adv. 2022; 6(2):533-543.","DOI":"10.1182\/bloodadvances.2021005794"},{"key":"73257","doi-asserted-by":"crossref","unstructured":"Sehn LH, Herrera AF, Flowers CR. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020; 38(2):155-165.","DOI":"10.1200\/JCO.19.00172"},{"key":"73258","doi-asserted-by":"crossref","unstructured":"Sun W, Liang AB, Huang H, Huang XJ. Strategies to optimize chimeric antigen receptor T-cell therapy in hematologic malignancies: Chinese experience. Haematologica. 2023; 108(8):2011-2028.","DOI":"10.3324\/haematol.2022.282316"},{"key":"73259","doi-asserted-by":"crossref","unstructured":"Ying Z, Yang H, Guo Y. Relmacabtagene autoleucel (relmacel) CD19 CAR-T therapy for adults with heavily pretreated relapsed\/refractory large B-cell lymphoma in China. Cancer Med. 2021; 10(3):999-1011.","DOI":"10.1002\/cam4.3686"},{"key":"73260","doi-asserted-by":"crossref","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022; 387(24):2220-2231.","DOI":"10.1056\/NEJMoa2206913"},{"key":"73261","doi-asserted-by":"crossref","unstructured":"Song YQ, Zhang HL, Huang HQ. Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma. Haematologica. 2024; 109(4):1269-1273.","DOI":"10.3324\/haematol.2023.283802"},{"key":"73262","doi-asserted-by":"crossref","unstructured":"Kahl BS, Hamadani M, Radford J. A phase I study of ADCT-402 (loncastuximab tesirine), a novel pyrrolobenzodiazepine-based antibody-drug conjugate, in relapsed\/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2019; 25(23):6986-6994.","DOI":"10.1158\/1078-0432.CCR-19-0711"},{"key":"73263","doi-asserted-by":"crossref","unstructured":"Caimi PF, Ai W, Alderuccio JP. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021; 22(6):790-800.","DOI":"10.1016\/S1470-2045(21)00139-X"},{"key":"73264","doi-asserted-by":"crossref","unstructured":"Zammarchi F, Corbett S, Adams L. ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. Blood. 2018; 131(10):1094-1105.","DOI":"10.1182\/blood-2017-10-813493"},{"key":"73265","doi-asserted-by":"crossref","unstructured":"Furqan F, Hamadani M. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data. Ther Adv Hematol. 2022; 13:20406207221087511.","DOI":"10.1177\/20406207221087511"},{"key":"73266","doi-asserted-by":"crossref","unstructured":"Caimi PF, Ai WZ, Alderuccio JP. Loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study. Haematologica. 2024; 109(4):1184-1193.","DOI":"10.3324\/haematol.2023.283459"},{"key":"73267","doi-asserted-by":"crossref","unstructured":"Hamadani M, Radford J, Carlo-Stella C. Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma. Blood. 2021; 137(19):2634-2645.","DOI":"10.1182\/blood.2020007512"},{"key":"73268","doi-asserted-by":"crossref","unstructured":"Alderuccio JP, Ai WZ, Radford J. Loncastuximab tesirine in relapsed\/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study. Blood Adv. 2022; 6(16):4736-4739.","DOI":"10.1182\/bloodadvances.2022007782"},{"key":"73269","doi-asserted-by":"crossref","unstructured":"Salles G, Duell J, Gonzalez Barca E. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020; 21(7):978-988.","DOI":"10.1016\/S1470-2045(20)30225-4"},{"key":"73270","doi-asserted-by":"crossref","unstructured":"Epperla N, Lucero M, Bailey T. Real-world clinical effectiveness of loncastuximab tesirine monotherapy for the treatment of relapsed\/refractory diffuse large B-cell lymphoma following chimeric antigen T cell therapy in the US. Transplant Cell Ther. 2024; 30(2):S353.","DOI":"10.1016\/j.jtct.2023.12.493"},{"key":"73271","doi-asserted-by":"crossref","unstructured":"Thapa B, Caimi PF, Ardeshna KM. CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. Blood Adv. 2020; 4(16):3850-3852.","DOI":"10.1182\/bloodadvances.2020002587"},{"key":"73272","doi-asserted-by":"crossref","unstructured":"Hess BT, Solh MM, Gandhi M. Phase 1b open-label study of loncastuximab tesirine in combination with other anticancer agents in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma (LOTIS-7). J Clin Oncol. 2023; 41(16_suppl):TPS7581.","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7581"},{"key":"73273","unstructured":"ADC Therapeutics announces updates on LOTIS-7 clinical trial evaluating ZYNLONTA\u00ae in combination with glofitamab or mosunetuzumab in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma [press release]. 2024."},{"key":"73274","doi-asserted-by":"crossref","unstructured":"Kwiatek M, Grosicki S, Jim\u00e9nez JL. ABCL-515 updated results of the safety run-in of the phase 3 LOTIS-5 trial: novel combination of loncastuximab tesirine with rituximab (Lonca-R) versus immunochemotherapy in patients with R\/R DLBCL. Clin Lymphoma Myeloma Leuk. 2023; 23:S439-S440.","DOI":"10.1016\/S2152-2650(23)01332-0"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.284973\/77486","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.284973\/78111","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11744\/77486","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:17Z","timestamp":1794046037000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.284973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.284973","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,5]]}}}